vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and NATIONAL FUEL GAS CO (NFG). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $425.9M, roughly 1.4× NATIONAL FUEL GAS CO). EXELIXIS, INC. runs the higher net margin — 40.8% vs 35.7%, a 5.2% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs 1.7%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 12.1%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
National Fuel Gas Company is a diversified energy company with $6.2 billion in assets distributed among the following five operating segments: Exploration and Production, Pipeline and Storage, Gathering, Utility, and Energy Marketing. National Fuel Gas was incorporated in 1902 and is based in Williamsville, New York.
EXEL vs NFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $425.9M |
| Net Profit | $244.5M | $152.0M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 81.5% |
| Net Margin | 40.8% | 35.7% |
| Revenue YoY | 5.6% | 1.7% |
| Net Profit YoY | 74.8% | — |
| EPS (diluted) | $0.89 | $1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $425.9M | ||
| Q4 25 | $597.8M | $637.9M | ||
| Q3 25 | $568.3M | $443.1M | ||
| Q2 25 | $555.4M | $527.4M | ||
| Q1 25 | $566.8M | $734.8M | ||
| Q4 24 | — | $513.8M | ||
| Q3 24 | $539.5M | $310.0M | ||
| Q2 24 | $637.2M | $338.6M |
| Q1 26 | $244.5M | $152.0M | ||
| Q4 25 | $193.6M | $181.6M | ||
| Q3 25 | $184.8M | $107.3M | ||
| Q2 25 | $159.6M | $149.8M | ||
| Q1 25 | $139.9M | $216.4M | ||
| Q4 24 | — | $45.0M | ||
| Q3 24 | $118.0M | $-167.6M | ||
| Q2 24 | $226.1M | $-54.2M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 86.6% | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | 94.7% | ||
| Q1 25 | 96.5% | 81.6% | ||
| Q4 24 | — | 87.3% | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | 98.5% |
| Q1 26 | 39.3% | 81.5% | ||
| Q4 25 | 39.6% | 43.3% | ||
| Q3 25 | 37.6% | 40.6% | ||
| Q2 25 | 33.6% | 43.7% | ||
| Q1 25 | 28.8% | 43.2% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | 25.2% | -63.4% | ||
| Q2 24 | 43.3% | -15.2% |
| Q1 26 | 40.8% | 35.7% | ||
| Q4 25 | 32.4% | 28.5% | ||
| Q3 25 | 32.5% | 24.2% | ||
| Q2 25 | 28.7% | 28.4% | ||
| Q1 25 | 24.7% | 29.4% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | 21.9% | -54.1% | ||
| Q2 24 | 35.5% | -16.0% |
| Q1 26 | $0.89 | $1.59 | ||
| Q4 25 | $0.69 | $1.98 | ||
| Q3 25 | $0.65 | $1.18 | ||
| Q2 25 | $0.55 | $1.64 | ||
| Q1 25 | $0.47 | $2.37 | ||
| Q4 24 | — | $0.49 | ||
| Q3 24 | $0.40 | $-1.81 | ||
| Q2 24 | $0.77 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | $300.0M |
| Stockholders' EquityBook value | $2.2B | — |
| Total Assets | $2.8B | $9.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $271.4M | ||
| Q3 25 | $791.1M | $43.2M | ||
| Q2 25 | $1.0B | $39.3M | ||
| Q1 25 | $1.1B | $40.0M | ||
| Q4 24 | — | $48.7M | ||
| Q3 24 | $1.2B | $38.2M | ||
| Q2 24 | $1.0B | $81.4M |
| Q1 26 | — | $300.0M | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $2.7B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.7B |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $3.6B | ||
| Q3 25 | $2.0B | $3.1B | ||
| Q2 25 | $2.1B | $3.0B | ||
| Q1 25 | $2.2B | $2.8B | ||
| Q4 24 | — | $-76.2M | ||
| Q3 24 | $2.3B | $-15.5M | ||
| Q2 24 | $2.1B | $5.0M |
| Q1 26 | $2.8B | $9.1B | ||
| Q4 25 | $2.8B | $9.2B | ||
| Q3 25 | $2.7B | $8.7B | ||
| Q2 25 | $2.8B | $8.4B | ||
| Q1 25 | $2.9B | $8.5B | ||
| Q4 24 | — | $8.3B | ||
| Q3 24 | $3.0B | $8.3B | ||
| Q2 24 | $2.8B | $8.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.75× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.99× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 532.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $657.3M |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | 117.0% |
| Cash ConversionOCF / Net Profit | 1.36× | 4.32× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | $657.3M | ||
| Q4 25 | $290.3M | $274.9M | ||
| Q3 25 | $49.0M | $237.8M | ||
| Q2 25 | $211.4M | $388.4M | ||
| Q1 25 | $240.3M | $253.8M | ||
| Q4 24 | — | $220.1M | ||
| Q3 24 | $271.3M | $197.9M | ||
| Q2 24 | $119.5M | $281.8M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-2.7M | ||
| Q3 25 | $46.2M | $-47.8M | ||
| Q2 25 | $208.5M | $195.3M | ||
| Q1 25 | $236.3M | $59.9M | ||
| Q4 24 | — | $-20.3M | ||
| Q3 24 | $263.1M | $-49.1M | ||
| Q2 24 | $113.0M | $79.5M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -0.4% | ||
| Q3 25 | 8.1% | -10.8% | ||
| Q2 25 | 37.5% | 37.0% | ||
| Q1 25 | 41.7% | 8.2% | ||
| Q4 24 | — | -4.0% | ||
| Q3 24 | 48.8% | -15.8% | ||
| Q2 24 | 17.7% | 23.5% |
| Q1 26 | 0.2% | 117.0% | ||
| Q4 25 | 0.2% | 43.5% | ||
| Q3 25 | 0.5% | 64.4% | ||
| Q2 25 | 0.5% | 36.6% | ||
| Q1 25 | 0.7% | 26.4% | ||
| Q4 24 | — | 46.8% | ||
| Q3 24 | 1.5% | 79.7% | ||
| Q2 24 | 1.0% | 59.7% |
| Q1 26 | 1.36× | 4.32× | ||
| Q4 25 | 1.50× | 1.51× | ||
| Q3 25 | 0.27× | 2.21× | ||
| Q2 25 | 1.32× | 2.59× | ||
| Q1 25 | 1.72× | 1.17× | ||
| Q4 24 | — | 4.89× | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
NFG
| Revenues from External Customers | $425.8M | 100% |
| Intersegment Revenues | $126.0K | 0% |
